Products

ArteraAI Prostate
ArteraAI
Oncology AI
ArteraAI Prostate is an AI-powered diagnostic test that provides prognostic and predictive insights for localized prostate cancer, aiding in personalized treatment decisions and improving patient outcomes.

See all 1 product →

About ArteraAI

ArteraAI is a leader in AI-powered precision medicine, developing multimodal artificial intelligence (MMAI) platforms to analyze digital pathology and clinical data for personalized cancer management. Their technology aims to provide actionable insights across multiple cancers, with a focus on personalizing cancer therapy.

The company’s flagship product, the ArteraAI Prostate Test, offers therapeutic insights for early-stage prostate cancer and can predict which NCCN Intermediate-risk patients will benefit from ST-ADT with radiation therapy. It is the first and only AI test included in the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer as a prognostic test.

Focus Areas

precision medicine medical AI cancer diagnostics oncology AI digital pathology computational pathology biomarker discovery prostate cancer breast cancer clinical decision support risk stratification

Business Intelligence

TechnologyMultimodal Artificial Intelligence (MMAI) platform that analyzes digital pathology and clinical data

What Physicians Need to Know

Precision Medicine & AI Cancer Therapy
ArteraAI specializes in precision oncology powered by AI, developing AI tools to enable clinicians to deliver individualized treatment plans.
Key Differentiators
ArteraAI utilizes a multimodal artificial intelligence (MMAI) platform that analyzes digital pathology and clinical data. Their tests are validated in numerous large, randomized phase III clinical trials. The ArteraAI Prostate Test is included in NCCN Guidelines for 3 separate indications and is the first and only AI test to be included as a prognostic test. It also achieved De Novo Authorization from the FDA as a first-of-its-kind AI-powered digital pathology risk stratification tool, regulated as Software as a Medical Device (SaMD).
Technology Stack
Their core technology is a multimodal artificial intelligence (MMAI) platform that analyzes digital pathology and clinical data.
Prostate Cancer Specialization
The ArteraAI Prostate Test offers therapeutic insights in early-stage prostate cancer, predicting which NCCN Intermediate-risk patients will benefit from ST-ADT with radiation therapy. It is also the first digital pathology-based test to provide individual risk estimates to help inform treatment planning in metastatic hormone-sensitive prostate cancer (mHSPC). The test uses image data from existing H&E slides, does not consume tissue, and provides rapid turnaround results (1-2 days).
Breast Cancer Specialization
The ArteraAI Breast Cancer Test provides 5- and 10-year distant metastasis risk for early-stage breast cancer patients and predicts which node-negative patients 50 years or older will benefit from chemotherapy.
Physician Tip

ArteraAI offers actionable insights across multiple cancers, specifically prostate and breast cancer. For prostate cancer, their test is included in NCCN Guidelines and can help identify intermediate-risk patients who benefit from specific therapies, as well as inform treatment planning for mHSPC. The test is non-invasive to tissue, using existing H&E slides, and provides rapid results. For breast cancer, it provides risk assessment for distant metastasis and helps predict chemotherapy benefit for certain patients.

Products by ArteraAI

1 product in the directory

ArteraAI Prostate
ArteraAI
Oncology AI
ArteraAI Prostate is an AI-powered diagnostic test that provides prognostic and predictive insights for localized prostate cancer, aiding in personalized treatment decisions and improving patient outcomes.

Videos

News, demos, and interviews about ArteraAI.

Loading videos...

Videos load interactively. If none appear, search YouTube for ArteraAI →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

The ArteraAI Prostate Test offers therapeutic insights in early-stage prostate cancer and can predict which NCCN Intermediate-risk patients will benefit from ST-ADT with their radiation therapy.
ArteraAI offers tests for prostate cancer from biopsy, post-radical prostatectomy, and metastatic hormone-sensitive prostate cancer (mHSPC).
The test analyzes image data from existing H&E slides, requiring no additional staining or preparation and does not consume tissue.
The ArteraAI Breast Cancer Test provides 5- and 10-year distant metastasis risk for early-stage breast cancer patients and predicts which node-negative patients 50 years or older will benefit from chemotherapy.
ArteraAI uses a multi-modal artificial intelligence (MMAI) platform that analyzes digital pathology and clinical data for personalized cancer management.
Results for the ArteraAI Prostate Test can be shared within 1-2 days after receipt of the patient’s specimen by their CLIA lab.

Related Companies

Spectrum Dynamics Medical is a pioneering medical device company focused on transforming nuclear medicine from analog to digital technology. They specialize in developing high-definition, solid-state based nuclear imaging technology, including digital SPECT (Single Photon Emission Computed Tomography) and SPECT/CT systems. Their products aim to meet the clinical needs and workflow demands of diagnostic imaging departments […]

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]

Siemens Healthineers is a leading global medical technology company that pioneers breakthroughs in healthcare. The company focuses on medical technology and diagnostics, offering a wide range of products including imaging systems, laboratory diagnostics, and advanced therapies. Their innovations aim to improve patient outcomes and make healthcare more accessible and sustainable. Siemens Healthineers has a strong […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

PathologyAILab offers advanced digital cytology services, leveraging a multi-agent AI system for cervical cancer diagnosis. This innovative solution provides comprehensive image analysis to deliver precise and reliable diagnostic insights to healthcare professionals. The service aims to provide rapid results, typically within 2-4 hours, for urgent cases, enabling timely clinical decisions. The process involves submitting digital […]

Varian Medical Systems, now a Siemens Healthineers company, is a global leader in advanced radiation oncology solutions for comprehensive cancer treatment. The company develops and manufactures medical devices and software for treating cancer and other medical conditions using therapies such as radiotherapy, radiosurgery, proton therapy, and brachytherapy. Their product portfolio includes linear accelerators (LINACs), proton […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.